Promising developments in tackling resistance to blood cancer drugs

13 abril 2015

A drug with the potential to reverse resistance to immunotherapy has been developed by scientists, showing great promise in pre-clinical models. Researchers say that it will be available to patients with certain leukemias and non-Hodgkin lymphomas in clinical trials later this year. Targeted drugs made from engineered immune proteins — called monoclonal antibodies — have revolutionized treatment for several types of cancer in recent years.